1Gotto FM.Lipid-lowering therapy for the primary prevention of coronary heart disease[J].J Am Coll Cardiol, 1999, 33: 2078-2082.
2Lennernas H.Fager G.Pharmacodynamics and pharmacodynamics of the HMG-COAreducfase inhibitors:Similarities and differences[J].Clin Pharmacd Kinet,1997,32:403-425.
5Byingto RP,Jukema JW,Salonen JT.Reduction in cardiovascular events during pravastain therapy.Pooled analysis of clinical events of pravastatin atherosclerosis intervention Program[J].Circulation,1995,92(4):2419-2425.
1[1]Carlsson CM, Carnes M, McBride PE et al. Managing dyslipidemia in older adults. J Am Geriatr Soc, 1999; 47∶1458～1465
2[2]Downs JR, Clearfiled M, Weis S et al. For the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA, 1998;279∶1615～1622
3[3]Shepherd J, Cobbe SM, Ford I et al. For the West Scotland Coronary Prevent Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med, 1995;333∶1301～1307
4[4]Pedersen TR, Kjekshus J, Pyorala K et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol, 1998; 81∶333～335
5[5]Plehn JF, Davis BR, Sacks FM et al. For the CARE investigators. Reduction of stroke incidence following myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) Study. Circulation, 1999; 99∶216～223
6[6]The long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Mend, 1998; 339∶1349～1357
7[7]Eastern Stroke, Coronary Heart Disease Colleborative Research Group. Blood pressure, cholesterol, and stroke in the eastern Asia. Lancet, 1998; 352∶1801～1807
8[8]Mascio RD, Marchioli R, Tognoni G. Cholesterol reduction and stroke occurrence: a overview of randomized clinical trials. Cerebrovas Dis, 2000; 10∶85～929
9[9]MRC/BHF Heart Protection Study of cholesterol lowering therapy and of anti-oxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease and death: early safety and efficacy experience. Eur Heart J, 1999; 20∶725～741
10[10]Gaw A, Shepherd J, Blaw GJ et al. Pravastatin in the prevention of cerebrovascular disease and its consequences in the elderly-the PROSPER design. Stroke, 1999;30∶251(Abstract)
6Faxaci FM. Role of nitric oxide in regulation of basilar artery tonein vivo. Am J Physiol, 1990,259 (4) :1216-1221.
7Casino PR , Kilcoyne CM, Quyyumi AA , et al. The role of nitric oxide in endothelium- dependent vasodilation of hypereholesterolemic patients. Circulation, 1993, 88 (6) :2541-2547.
8Anggard E. Nitric oxide mediator muderer and medicine. Lancet, 1994, 343(8907) :1199- 1206.
9Kardami E , Padue RR , Pasumarthi KBS , et al. Expression, localization and effects of basic fibroblast growth factor oncardiac myocytes. In : kardami E. Growth factors and the cardiovascular system. Winnepeg :P. Cummins. Kluwer Academic Publishers ,1993: 55-76.
10Grundy SM,Cleeman.JI,Merz CN,et al.Implications of recent clinical trails for the national cholesterol education program adult treatment penel III guidelines[J].Circulation,2004,110(2):227-239.
